新股消息 | 邦顺制药递表港交所
智通财经网·2026-01-22 10:41
Group 1 - The core viewpoint of the article is that Hangzhou Bangshun Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the sole sponsor [1] - Bangshun Pharmaceutical is a biotechnology company nearing commercialization, focusing on oncology and autoimmune diseases [1] - The company has established a pipeline that includes one new drug application candidate (Bezeqitinib), one clinical-stage candidate (CX1440), and five preclinical candidates (CX03, CX12, CX13, CX15, and CX16) [1]